Diagnosing FSGS without kidney biopsy – a novel INF2-mutation in a family with ESRD of unknown origin by Johannes Münch et al.
CASE REPORT Open Access
Diagnosing FSGS without kidney biopsy – a
novel INF2-mutation in a family with ESRD
of unknown origin
Johannes Münch1, Maik Grohmann2, Tom H. Lindner1, Carsten Bergmann2 and Jan Halbritter1*
Abstract
Background: Patients on renal replacement therapy are often unaware of their underlying condition and hence
suffer from so-called end-stage renal disease (ESRD) of unknown origin. However, an exact diagnosis is not only
important for better estimating the prognosis, but also when preparing for kidney transplantation. Whilst patients
with FSGS without a confirmed genetic cause have a high recurrence rate in the transplanted organ, patients with
a mutation generally exhibit no recurrence and have a good prognosis. Furthermore, renal biopsy, which may be
helpful for differential diagnosis, is usually contraindicated in end-stage kidneys. We here present the case of familial
ESRD of unknown origin, which could be resolved by targeted genetic testing prior to planning of kidney transplantation.
Case presentation: A 32-year-old female with ESRD and nephrotic range proteinuria was admitted to our clinic.
Family-history revealed that both mother and maternal grandmother had ESRD of unknown origin. As renal biopsy was
impossible due to atrophic kidneys, we performed mutation analysis of genes known for dominant forms of FSGS and
found a novel heterozygous mutation of INF2 (c.485 T > C, p.Leu162Pro). The same mutation could be detected in the
index patient’s mother (ESRD at age 50) and three brothers with normal serum-creatinine but mid or low range proteinuria.
Conclusions: Genetic testing is warranted in families with ESRD of unknown origin and may provide a robust diagnosis
even without kidney biopsy. It will help detecting relatives at risk who have to be excluded from potential kidney donation
and who may benefit from timely initiation of protective measures in order to slow down disease progression.
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Background
Unfortunately, ignorance of the underlying renal condi-
tion is a common phenomenon among patients on renal
replacement therapy. This is often due to late clinical
presentation at stages of advanced disease, when import-
ant diagnostic tools, such as kidney biopsy, are no longer
possible for diminished organ size and consecutive risk
of bleeding. Focal segmental glomerulosclerosis (FSGS)
is such an underlying, potentially underdiagnosed, con-
dition. FSGS is derived from its histological appearance
upon kidney biopsy and represents a strictly descriptive
term that comprises heterogeneous disorders which
altogether represent a major cause of nephrotic syn-
drome, progressive renal failure, and end-stage renal
disease (ESRD) [1]. It is characterized by focally occur-
ring glomeruli with segmental capillary sclerosis and
podocytic foot-process effacement upon light and elec-
tron microscopy. Apart from secondary causes, such as
obesity, infections, drugs, and others, more than 30
single-gene causes have been identified over the past
decades [2]. By unraveling those genetic causes, the
knowledge on podocytes and the essential role of the
actin cytoskeleton for the integrity of the glomerular
filtration barrier has expanded dramatically [3]. The
most common cause of autosomal-dominant FSGS in
adults is thought to be due to mutations in the gene
INF2 [4], which encodes a member of the so called
formin family of proteins that are supposed to sever
actin filaments and accelerate their polymerization
and depolymerization [5]. INF2-gene mutations were
identified in both FSGS and Charcot-Marie-Tooth dis-
ease, a hereditary motor and sensory neuropathy that
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is characterized by peripheral nerval demyelination [6].
Virtually all disease-causing mutations of the INF2 gene
associated with FSGS have been found within exons cod-
ing for its highly conserved diaphanous-inhibitory domain
(DID), which serves as a regulator for polymerization and
depolymerization of actin filaments [7]. In contrast to
many other genetic forms of FSGS, patients with INF2-
mutations do usually not manifest before adolescence or
early adulthood and age at ESRD can vary significantly
(published data range 12–70 years) [6–8].
Case presentation
The index patient, a 32-year-old Caucasian female with
proteinuria (5.7 g/g creatinine) and impaired renal func-
tion (serum creatinine 222 μmol/l, eGFR-CKD-EPI
24 ml/min/1.73 m2), was admitted to our nephrology de-
partment. Except for edema of the legs, physical examin-
ation showed no further abnormalities, in particular, no
indication of a sensorimotor or other neurological dis-
order. Both kidneys presented atrophic on ultrasonog-
raphy (Fig. 1) with a hyperechogenic and diminished
renal parenchyma. We therefore decided not to perform
kidney biopsy for risk of hemorrhagic complications.
Blood pressure was slightly elevated, in the range of
140–150 mmHg systolic. No other mentionable laboratory
abnormalities, including normal auto-antibody screening
(anti-nuclear = ANA, anti-neutrophil cytosplasmatic =
ANCA), were noted.
Family history yielded ESRD of unknown etiology in
her 53-year-old mother, since the age of 50, and a non-
specified kidney disease in her already deceased mater-
nal grandmother. In suspicion of a dominantly inherited
disorder with progressive nephrotic syndrome, we initi-
ated genetic testing for the most common single-gene
causes of dominant familial FSGS. Sequencing of actinin
alpha 4 (ACTN4) was unremarkable. Direct sequencing
of inverted formin 2 (INF2), however, showed a hetero-
zygous nucleotide exchange from thymine to cytosine
(c.485 T > C) in exon 3, resulting in the substitution of a
highly conserved leucine to proline at amino acid pos-
ition 162 (p.Leu162Pro) (Fig. 2). Upon confirmatory ana-
lysis, we could prove familial segregation and the same
mutation was present in her 53-year-old mother. We
subsequently screened all available family members for
the presence of proteinuria and identified increased
levels of urinary albumin in three brothers of the index
patient, none of them with remarkable rise of serum cre-
atinine (III-1 33 years: 1600 mg/g creatinine, III-3
28 years: 451 mg/g creatinine, III-4 20 years: 177 mg/g
creatinine). The familial INF2-mutation was detected in
all three affected brothers (Fig. 2, Table 1), who were
consecutively started on treatment with an ACE-
inhibitor and informed about general measures of kidney
protection. In light of the genetic diagnosis, the affected
brothers were excluded as potential living kidney donors
for the index patient and her mother. Unfortunately, the
index patient rapidly progressed to ESRD with an eGFR
of 15 ml/min within 10 months of first presentation.
Conclusions
We here report a novel INF2-mutation (c.485 T > C,
p.Leu162Pro) in a family with ESRD of previously un-
known etiology. As in virtually all patients with FSGS
due to mutated INF2, the detected mutation is located
within the first exons and results in an amino acid
change within the functionally important N-terminal
DID [9]. Involvement of the same codon was previously
described in a study by Caridi et al. (2014), however,
resulting in yet another aa-substitution (p.Leu162Arg)
[7]. As kidney biopsy was rejected for risks of bleeding,
Fig. 1 Abdominal ultrasonography of index patient. Right kidney is overall diminished in size (a-b: 88 × 33 mm, c: renal parenchyma 8 mm) and
appears hyperechogenic compared to liver parenchym
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Fig. 2 a Pedigree with affected family members denoted by black fillings, the index patient (III-2) is indicated by a red arrow. b Heterozygous
INF2-mutation (c.485 T > C) present in all affected family members, indicated as MT for mutant and WT for wildtype. c Highly conserved amino
acid-residue leucine (p.162), altered to proline in affected family members, located within the N–terminal DID-domain. Legend: ESRD, end-stage
renal disease; H.s., Homo sapiens; M.m., Mus musculus; G.g., Gallus gallus; X.l., Xenopus laevis; D.r., Danio rerio; PU, proteinuria
Table 1 Clinical characteristics of affected family members







c.485 T > C
p.Leu162Pro
(het)
32 5700 222/15 NA/atrophic kidneys
Mother (II-1)
53 years
c.485 T > C
p.Leu162Pro
(het)
50 NA >300/<15 NA/atrophic kidneys
Bother1 (III-1)
33 years
c.485 T > C
p.Leu162Pro
(het)
NA 1600 95/98 NA/normal kidneys
Brother2 (III-3)
28 years
c.485 T > C
p.Leu162Pro
(het)
NA 451 78/116 NA/normal kidneys
Brother3 (III-4)
20 year
c.485 T > C
p.Leu162Pro
(het)
NA 177 77/124 NA/normal kidneys
ESRD end-stage renal disease, het heterozygous, NA not annotated, yr years
acDNA mutations are numbered according to human cDNA reference sequence NM_022489.3 (INF2), where +1 corresponds to the A of ATG start
translation codon
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this family illustrates nicely the diagnosis of FSGS, solely
based on a robust molecular genetic diagnosis. Based on
the initial findings of the index patient and her mother,
we successfully screened for further family members at
risk and found three brothers with normal kidney func-
tion but asymptomatic proteinuria (<2 g/g creatinine). In
all five affected family members alive, the familial INF2-
mutation was found in heterozygous state (Fig. 2), while
family members without proteinuria were tested wildtype.
Interestingly, the clinical course was markedly variable,
with the most severe affection in the index patient (ESRD
at 32). At this point, it remains speculative whether un-
identified genetic or environmental modifiers may account
for these phenotypic differences.
As previously shown by Sun et al. (2013), the resulting
dysfunction of INF2 is responsible for a deranged struc-
ture of the cytoskeleton, leading to an abnormal distribu-
tion of podocin and nephrin as important components of
the podocytic slit membrane [10]. Disturbed intra- and
transcellular transportation of proteins due to an impaired
polymerization and depolymerization of actin filaments
may be the reason for these histological findings [10]. To
date, there is no causative medical treatment of FSGS due
to defective INF2. Renal transplantation, however, can be
considered a curative treatment for patients without
neurological manifestation (Charcot-Marie-Tooth dis-
ease), provided the donor kidney expresses functional
INF2. Therefore, a thorough evaluation of potential
living kidney donors is indispensable. As illustrated in
our family, the clinical picture can be extremely vari-
able. A definite and valid exclusion of the disease will
only be possible by genetic testing. In case of timely
diagnosis at an early stage of disease (III-1, III-3, III-4),
anti-proteinuric medication with inhibitors of the renin-
angiotensin-aldosterone-system should be initiated. Apart
from ACE-inhibitors and AT1-blockers, aldosterone an-
tagonists (e.g., spironolactone) might offer an alternative
therapeutic option, as aldosterone seems to also have a
direct influence on several podocytic processes, like the
generation of stress fibers and inducing the disassembly of
cortical actin- and cell-cell-junctions [11, 12].
In conclusion, we strongly suggest genetic testing in
younger patients with a positive family history but ESRD
of unknown origin: i) targeted genetic testing based on
clinical suspicion provides a reasonable likelihood of de-
tecting the underlying condition even when kidney biopsy
is contraindicated, ii) knowledge of the causative renal dis-
order is highly informative for risk-assessment and plan-
ning of kidney transplantation (e.g., risk of recurrence), iii)
consecutive detection of family members at risk will help
to exclude potential living kidney donors within the fam-
ily, iv) timely initiation of reno-protective measures will
help affected family members to slow down disease pro-
gression and protract or even avoid ESRD.
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